TIMEPOINT of visit/assessment | Baseline | 15 days (call interview) | 3 months | 6 months- end of the study |
---|---|---|---|---|
Enrollment | ||||
Information and informed consent | ✓ | |||
Randomization-allocation | ✓ | |||
Interventions | ||||
Probiotic Intervention Placebo Intervention |
| |||
Assessment | ||||
Physical examination including anthropometric measures and abdominal tenderness | ✓ | ✓ | ✓ | |
Drug compliance and adverse event assessment | ✓ | ✓ | ✓ | |
Weekly food diaries | ✓ | ✓ | ||
ADI-R | ✓ | |||
Outcome measures | ||||
ADOS 2 | ✓ | ✓ | ||
CARS | ✓ | ✓ | ||
RBS-R | ✓ | ✓ | ✓ | |
Sensory Profile | ✓ | ✓ | ✓ | |
SCQ | ✓ | ✓ | ✓ | |
GI Severity Index | ✓ | ✓ | ✓ | |
CBCL 1.5-5 | ✓ | ✓ | ✓ | |
PSI | ✓ | ✓ | ✓ | |
VABS-II | ✓ | ✓ | ||
Mc Arthur-CDI | ✓ | ✓ | ✓ | |
GMDS-ER | ✓ | ✓ | ||
Blood sample: LPS, Leptin, Resistin, TNF-α, IL-6, PAI-1 | ✓ | ✓ | ||
Urinary sample: Phtalates | ✓ | ✓ | ✓ | |
Fecal sample: Calprotectin | ✓ | ✓ | ✓ | |
High-density EEG registration: power, asymmetry index and coherence in the different frequency bands | ✓ | ✓ |